Purpose: To determine the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT) and the recommended dose of docetaxel in combination with doxorubicin, and to evaluate the activity in patients with advanced breast cancer.
Introduction
Docetaxel has demonstrated high antitumor activity as a single agent when used as first-or second-line chemotherapy for metastatic breast cancer [1] [2] [3] [4] . Moreover in patients with strictly defined anthracycline-resistant disease, docetaxel produced the highest activity reported to date [5, 6] in this setting, suggesting at least the absence of complete clinical cross resistance between the two drugs. Given this important activity and the well established role of doxorubicin in metastatic breast cancer, we designed a dose finding study of the combination to exploit the maximum benefit from these two drugs and to explore whether a higher activity can be reached without any increase of toxicity. The preclinical in vivo evaluation does not suggest any therapeutic synergism between docetaxel and doxorubicin [7] , but in the clinical setting even additive activity with these two very effective drugs could represent a major advance over current therapies.
Early clinical results obtained with paclitaxel and doxorubicin [8] showed promising activity in patients with previously untreated metastatic breast cancer. However, preliminary data from this trial clearly suggested a drug-sequencing-dependent toxicity, with the sequence of paclitaxel 24-hour i.v. infusion followed by 48 hours i.v. continuous infusion of doxorubicin being more toxic than the reverse [8] . This was later confirmed by a pharmacokinetic study which demonstrated that doxorubicin clearance was reduced by an average of 30% in those patients receiving paclitaxel before doxorubicin [9] . For this reason, we designed our study using the putatively less toxic sequence (i.e., doxorubicin i.v. bolus followed by docetaxel one-hour i.v. infusion).
The primary objective of this study was to determine the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT) and the recommended dose of the combination in women with previously untreated metastatic breast cancer. The one hour interval between the end of doxorubicin and the start of docetaxel infusion was selected empirically to minimize the risk of a pharmacokinetic interaction between the two drugs. Finally, given the potential cardiotoxicity of doxorubicin [10] [11] [12] , strict cardiac monitoring was performed in order to detect any cardiac events at an early stage.
Patients and methods
Between April 1994 and November 1995, 42 patients with previously untreated metastatic breast cancer were entered into this study. Eligible patients had to satisfy the following criteria: age 18 to 75 years, histologically proven metastatic breast cancer (histological or cytological proof of metastasis was required for patients with a single metastatic target lesion), WHO performance status ^ 2, measurable and/or evaluable disease. Normal hematologic and blood chemistry values were mandatory: adequate bone marrow (absolute neutrophil count (ANC) > 2000/ul, platelet count ^ 100 000/ul), hemoglobin (> 10 g/dl), liver function (serum bilirubin level ^ 1.25 times the upper limit of normal value (LNV), AST or ALT <2 times the upper LNV, alkaline phosphatase $ 6 times the upper LNV) and renal function (serum creatinine $ 140 umol/1), and normal baseline left ventricular ejection fraction (LVEF). Patients were excluded if they had received prior chemotherapy for metastatic disease, although neoadjuvant and/or adjuvant treatment were permitted provided there had been a chemotherapy-free interval of at least 12 months before study entry. Patients were ineligible if they had received prior therapy with taxoids. With respect to prior adjuvant anthracyclines, the maximum permitted cumulative doses prior to study entry were doxorubicin $ 300 mg/m 2 or epirubicin <500 mg/m 2 or pirarubicin <500 mg/m 2 , with the exception of patients who were to receive the highest planned dose of doxorubicin (60 mg/m 2 ), in whom the total prior doses were <200, 300 and $300 mg/m 2 , respectively. In designing the study it was assumed that most patients would have prior exposure to anthracycline and therefore a maximum number of six cycles was specified. No maximum on study cumulative dose of anthracycline was prospectively specified in the protocol. The protocol was approved by the ethics committee of Kremlin Bicetre and all patients gave written informed consent before accrual.
Patients were excluded for the following reasons: history of prior malignancies (excluding non-melanoma skin cancer or excised cervical carcinoma), known CNS metastases, symptomatic peripheral neuropathy grade ^ 2 and other coexisting medical problems that were not adequately controlled. Concurrent treatment with other anticancer or experimental drugs was prohibited. Patients with impaired liver function (AST and/or ALT > 1.5 times upper LNV associated with alkaline phosphatase > 2.5 times upper LNV) were also excluded from the study.
Treatment plan
Doxorubicin was administered as a 15 min intravenous (i.v.) bolus followed by docetaxel. There was an interval of one hour between the end of doxorubicin treatment and the start of docetaxel infusion. Docetaxel (Taxotere®) was supplied by Rhone-Poulenc Rorer (Antony, France) as a concentrated sterile solution in vials that contained 80 mg of drug formulated in 2 ml of polysorbate 80 (Tween 80®). The appropriate amount of docetaxel was diluted in 5% dextrose or 0.9% saline to a final concentration not greater than 1 mg/ml and administered as a one-hour i.v. infusion. Docetaxel and doxorubicin were administered on an outpatient basis every three weeks, without the support of prophylactic or curative G-CSF.
To avoid hypersensitivity reactions and to prevent the occurrence of docetaxel-induced skin toxicity and fluid retention, all patients were given a three-day corticosteroid prophylactic premedication, starting the day before chemotherapy. Oral dexamethasone 8 mg was administered 13, 7 and 1 hour before docetaxel and 6, 12, 18, 24, 30, 36 and 42 hours post-infusion. Cetirizine 10 mg orally was given seven and one hours before docetaxel, and ranitidine 300 mg orally was given once daily for three days, commencing the day prior to docetaxel administration. Anti-emetic premedication for doxorubicin was required for all patients and was given according to the normal practice of each investigator.
Treatment with docetaxel and doxorubicin was planned for a maximum of six cycles unless there was evidence of disease progression, unacceptable toxicity, patient refusal or stable disease without any improvement in symptoms after four cycles. Treatment thereafter depended on the response observed within the first six cycles. Patients in whom either objective responses or stable disease and symptomatic improvement were observed after six cycles could continue treatment with single-agent docetaxel (dose at the discretion of the investigator) until disease progression, unless serious toxicity or patient refusal occurred earlier.
Dose-escalation and dose modifications
Six escalating dose levels of docetaxel and doxorubicin were planned (Table 1) . Doses were assigned at registration and no dose-escalation was allowed in individual patients. Three patients were treated at each dose level with a one-week interval between entry of the first patient and the next two patients. Before escalating to the next dose level, at least three patients had to have received at least one cycle and been observed for acute toxicity for 3; 2 weeks. If one of three patients at a given dose level developed a DLT, three more patients were entered at the same dose level. The entry of more than three patients was allowed at the highest dose levels in order to ascertain the safety profile in a larger sample size. However, the MTD was defined as the dose at which > 2 of the first three entered or > 3 of the first six entered patients developed DLT. Dose modifications were recommended for acute and chronic toxicity such as febrile neutropenia, unresolved neutropenia, or grade 3 or 4 non-hematologic toxicity. In the case of DLT or severe toxicity, treatment was discontinued until the toxicity resolved to grade < 1 and then restarted for the subsequent cycle at the dose level below and/or with dose modification according to the toxicity observed.
Definition of dose-limiting toxicity
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC). DLT was defined as follows: grade 4 neutropenia (ANC <500/ul) that lasted >7 days, febrile neutropenia (grade 4 neutropenia + grade 2 fever requiring i.v. antibiotics and/or hospitalization) lasting > 3 days; grade 4 thrombocytopenia; grade 3-4 bleeding; grade 3-4 infections; grade 2 neurotoxicity, or any other grade 3 or 4 non-hematologic toxicity.
Patient and treatment evaluation
Prestudy evaluation included medical history and physical examination; tumor measurements; radiology (chest X-ray, liver echography or CT scan, bone scan, MRI or X-rays on hot spots and other examinations as clinically indicated); electrocardiogram (ECG); left ventricular ejection fraction (LVEF) determined by echocardiography or angioscintigraphy; complete blood count (white blood cells with differential, platelets, hemoglobin); serum and urine biochemistry and liver function tests. Patients were monitored for toxicity at least weekly throughout treatment. Tumor measurements were repeated every two cycles and a complete blood count was performed twice weekly or every two days in case of febrile neutropenia or grade 4 neutropenia until recovery. (21) 15 (36) 12 (29) 15 (36) 33 (79) 16 (38) 18 (43) 14 (33) 25 (59) 22 (52) 152 82-247 LVEF was measured every two cycles and then prior to each cycle after a total cumulative dose of doxorubicin of 400 mg/m 2 . A consistent method of evaluation at all assessments was required. LVEF decrease was denned as a decrease in LVEF of 10% (absolute units) in association with a decline below 50% (Schwartz criteria [12] ). The calculation of the total cumulative dose was to include anthracycline received in the adjuvant setting for those patients who entered the study with previous exposure. Prior epirubicin was converted to doxorubicin equivalent by dividing by 1.8 (e.g., 120 mg/m 2 epirubicin/1.8 = 66.6 mg/m 2 doxorubicin equivalent). Patients were followed up for at least one month following the final cycle of treatment in order to document any late adverse events.
Tumor response was assessed according to the WHO criteria [13] . All tumor responses recorded in the entire patient population were reviewed by an independent radiologist.
The duration of response (CR and PR) was calculated from the start of treatment until the first documentation of progressive disease, while the duration of complete response (CR) was calculated from the first time the CR was documented. Time to first response and time to progression were calculated from the first administration of the drugs to the first occurrence of response and first progression, respectively.
Patients who had received further antitumor treatment before progression were censored at the start date of the alternative treatment or at the date of the last assessment before further antitumor therapy. Survival was calculated from the date of the first administration of the combination to death.
Results

Patient characteristics
Forty-two patients with previously untreated metastatic breast cancer were enrolled into the study ( Table 2 ). The median age was 48.5 years and the median PS was 0. Almost two-thirds of patients had two or more involved organs; 33 patients (79%) had visceral disease, with liver involvement in 18 patients (43%). Sixteen patients (38%) had bone involvement. Twenty-five patients (59%) had received prior adjuvant chemotherapy, including twentytwo (52%) who had received anthracycline-containing adjuvant chemotherapy. The median cumulative dose of prior doxorubicin or equivalent was 152 mg/m 2 (range 82-247 mg/m 2 ).
In total, 350 cycles were administered during the study: 286 (82%) with the combination (Table 3) and 64 (18%) with single-agent docetaxel. Overall, the median number of cycles (including cycles with single-agent docetaxel) administered was 8 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and the median number of cycles administered with the combination was 7 (range 2-10). Twenty-two patients received more than six cycles of the combination, contrary to protocol recommendation. Among these 22 patients, 12 had received prior adjuvant anthracycline chemotherapy with a median cumulative dose of 143 mg/m 2 (range 90-194). Twenty-one patients (50%) continued treatment with docetaxel alone once the maximum cumulative dose of doxorubicin or the maximum number of cycles recommended by the protocol were reached, or when the investigator deemed it necessary. The median total cumulative dose of doxorubicin for the 21 patients treated with single agent docetaxel was 454 mg/m 2 (range 276-559). The median number of cycles of docetaxel monotherapy was 3 (1-6) and the majority of these were administered at a starting dose of 75 mg/m 2 . The median actual doses of docetaxel and doxorubicin were 2 , the MTD) at which the RDI was 0.89. Most treatment cycles (91%) with the combination were administered every three weeks as specified in the protocol; 6.6% of cycles were delayed by ^1 week and 2.4% of cycles were delayed by > 1 week. Half of the delayed cycles (13 of 26) were delayed as a result of toxicity. The doses of doxorubicin and docetaxel were decreased in 3.5% and 4.9% of cycles, respectively, primarily because of hematological and non-hematological toxicities.
Toxicity
All 42 patients were assessable for toxicity, and the analysis included all cycles with the combination. The main reasons for treatment discontinuation were as follows: 27 patients (64.3%) completed the treatment as per protocol, 9 patients (21.4%) withdrew due to disease progression (none before the fourth cycle and three after an initial response), 5 (11.9%) withdrew due to toxicity (febrile neutropenia 2, grade 2 paresthesia 1, moderate asthenia 1, and moderate fluid retention 1) and 1 patient refused further treatment after receiving six cycles with the combination although the treating oncologist recommended continuing treatment.
Neutropenia and its complications were the dose limiting toxicity of this combination; no grade 3-4 nonhematological toxicity was observed and no major differences in the incidence or severity of hematological and non-hematological toxicities were observed after dose level 2. The MTD was found at dose level 5 using docetaxel 85 mg/m 2 in combination with doxorubicin 50 mg/m 2 ; the DLTwas severe infection which occurred in two patients. It was decided not to put a sixth patient at risk with this dose level to simply confirm the MTD as prospectively denned. The recommended dose for phase II-III studies was established at dose level 4 (50/75 mg/m 2 ). As another standard dose of doxorubcin in combination is 60 mg/m 2 , dose level 6 (60/60 mg/m 2 ) was also tested and can be recommended.
Neutropenia was observed in all patients, with 93% experiencing grade 4 episodes (Table 4) . Grade 4 neutropenia was generally brief, with a median duration of five days (range 1-13). In addition, recovery from neutropenia occurred in time for the administration of the next cycle in most cases. At every dose level the median number of neutrophils at day 22 ± 3 was greater than 2 x 10 3 /l. Febrile neutropenia requiring IV antibiotics and/or hospitalization occurred in 16 (38%) patients and in 10% of treatment cycles. Episodes of febrile neutropenia were also brief, with 83% lasting ^ 3 days. The highest incidence was observed at the dose level combining docetaxel 75 mg/m 2 with doxorubicin 50 mg/m 2 . However, at this dose level, only one episode of grade 3 infection occurred during the sixth cycle. As seen in Table 4 , the duration of febrile neutropenia was brief, treated without G-CSF, and in many cases the treating oncologist did not feel that it required any corrective action at the next cycle. In the 16 patients with at least one episode of febrile neutropenia the summary of corrective actions taken for the next cycles was none in 6 patients, dose reduction in 7 patients, dose reduction and delay in 2 patients and only one patient received prophylactic G-CSF in addition to dose reduction and treatment delay. There were 30 cycles given following an episode of febrile neutropenia in the six patients with no action taken for those subsequent cycles. Of these 30 cycles administered at full dose, only one further episode of febrile neutropenia was observed.
Although anemia was noted in all patients (19% of whom had grade 1 or 2 anemia at baseline), grade 3 Table 5 . Acute and chronic non-hematological toxicities considered possibly or probably related to study treatment in 42 patients evaluable for safety. episodes were uncommon (9.5% of patients). Grade 3 thrombocytopenia was also rare, occurring in three patients.
The most common acute non-hematologic toxicities that were observed during the study are shown in Table 5 . Gastrointestinal toxicities were mild, with no grade 3-4 stomatitis, nausea, vomiting or diarrhea observed at any dose level. Skin toxicity was frequent but mild. Neurotoxicity was grade 1 peripheral neuropathy in 25 patients and grade 2 in 1 patient. Asthenia and nail disorders were usually mild to moderate. Alopecia was universal.
The median cumulative dose of docetaxel, including cycles with single-agent docetaxel was 610.5 mg/m 2 (range 199-1010). Mild to moderate fluid retention was observed in 31 patients (74%); no severe cases were seen and 1 patient discontinued treatment because of fluid retention.
With a median follow-up period of 29 months (range 9+-41), and a median cumulative dose of doxorubicin (including prior adjuvant doxorubicin or equivalent) of 392 mg/m 2 (range 240-559) or 310 mg/m 2 (99-534) when excluding prior adjuvant anthracyclines, no congestive heart failure (CHF) was observed (Table 6) . Furthermore, among the 11 patients (26.2%) who received more than 480 mg/m 2 of doxorubicin (including prior adjuvant anthracycline) no symptomatic cardiac event was observed. LVEF decrease was observed in four (9.5%) patients with absolute decreases of 12 percentage points in three and 19 points in one, no patient had a LVEF decrease below 40%. All but one patient had prior mediastinal radiotherapy and two patients had received adjuvant anthracyclines, at doses of 180 and 247 mg/m 2 , respectively. In three patients, the LVEF value returned to normal (^50%) either during treatment or during the follow-up period. In the last patient, LVEF remained lower than 50%. No patient has shown any cardiac symptoms (Table 7) . 
Responses
All patients were assessable for antitumor response which were reviewed by an independent radiologist. Response rates are listed in Table 8 . The combination was active at all dose levels. The overall response rate for the 42 treated patients (intent-to-treat analysis) was 71% (95% CI: 55.4-84.3), including 2 complete and 28 partial responses. The remaining 12 patients had disease stabilization as best overall response. No patient had progressive disease without some period of stabilization or response. The response rate appeared to be higher in patients treated at dose levels 3-6, with an overall response rate of 81% (95% CI: 62.5-92.5) across these dose levels. The median time to first response was 9.3 weeks (range 2.9-31.9). The activity appeared uniform across negative prognostic factors, with responses seen in patients with major organ involvement and bone involvement (Table 8) . A Table 8 . Antitumor activity of docetaxel plus doxorubicin in 42 patients with previously untreated advanced breast cancer (intent-totreat). response rate of 73% was observed in the 22 patients who had received prior adjuvant anthracyclines. Among the 30 responders, only 5 had an actual progression of disease before being censored. Because this will induce a bias in the estimation of median duration of response it is most appropriate to provide the range of duration of response, which was 6+-62 weeks. Duration was censored in 25 of 30 responding patients; the reasons for censoring before disease progression comprised further hormonotherapy (n = 17), chemotherapy (n -5), chemo-hormonotherapy (n = 2), surgery (n -1) and no documentation of PD at the study cut-off date (n -1).
The median time to disease progression was 46 weeks (6+-62). After a median follow-up time of 29 months (range 9+-41), 15 patients (36%) had died and 27 (64%) were still alive. The median survival has not been reached and the two-year survival was 66%.
Discussion
In our trial, docetaxel and doxorubicin were administered as first-line chemotherapy in the outpatient setting without the support of prophylactic colony stimulating factors. The patient population entered in this study was representative of metastatic breast cancer patients commonly referred for treatment and more than 50% had previously been exposed to anthracycline-based chemotherapy received in the adjuvant setting.
This phase I study established an MTD with 85 mg/m 2 of docetaxel and 50 mg/m 2 of doxorubicin. The doselimiting toxicity was grade 3 infection which occurred in two out of the five patients treated at this dose level. Two doses were recommended for phase II-III studies. Dose level 4 (50 mg/m 2 docetaxel and 75 mg/m 2 doxorubicin) represents a feasible dose level with the highest apparent activity. Dose level 6 (60 mg/m 2 docetaxel and 60 mg/m 2 doxorubicin) may be interesting for future researchers since a higher dose intensity of doxorubicin can be delivered without any increase in acute or chronic toxicities.
Overall, it was routinely possible to give this combination on schedule. Interestingly, despite the fact that the protocol specified six cycles of the combination as the maximum, we continued treatment for responding patients considering it to be in the patient's best interest. In these cases we felt that the maximum number of cycles was not as important as the total cumulative dose of doxorubicin which must not exceed 550 mg/m 2 with careful cardiac monitoring. Routine LVEF monitoring (every two cycles) was increased to every cycle once the cumulative anthracycline dose of 400 mg/m 2 was reached. This cumulative dose includes anthracycline received in the adjuvant setting for those patients who entered the study with previous exposure (allowed by protocol). The combination was generally well tolerated at all dose levels. No grade 3-4 or severe non-hematologic toxicities were observed across the different dose levels. Importantly, no grade 3-4 stomatitis was observed, even at the highest dose levels.
As expected with these two hematotoxic drugs, grade 4 neutropenia was observed in 93% of patients but was brief in duration, with recovery at day 21. Febrile neutropenia was observed in 38% of patients and in 10% of cycles. However, these episodes were brief (no curative G-CSF was given) and did not affect the median relative dose intensity of either docetaxel or doxorubicin, which were 0.96 (0.7-1.01) and 0.97 (0.68-1.01), respectively. Grade 3 infection occurred in three patients, two of whom were entered at the MTD of the combination. Dose reduction and/or treatment delay were recommended for instances of febrile neutropenia but this was not done in all cases. The lack of compliance with the dose adjustment recommended is at least partially explained by the duration of the febrile neutropenia. The treating oncologist considered many episodes of febrile neutropenia short enough and without signs of high risk to allow maintenance of the same dose intensity at the next cycle without adding G-CSF. In the six patients (30 cycles) who received a maintained dose intensity, only one episode of febrile neutropenia occurred.
We consider the hematologic toxicity of this combination to be manageable and within the acceptable range for the first-line metastatic setting, where a high proportion of long lasting responses is an important goal.
Cumulative toxicities previously described with singleagent docetaxel [15, 16] were also infrequent and easily manageable in our trial. Fluid retention was a minor clinical problem since it was never severe and only one patient withdrew as a result of this toxicity, after receiving 10 cycles and a cumulative docetaxel dose of 736 mg/m 2 . The decrease in both the incidence and severity of fluid retention is probably related to the use of the three-day corticosteroid premedication that has shown similar efficacy to a five-day regimen in the prevention of fluid retention [17] . Despite a high cumulative dose of docetaxel (median 610 mg/m 2 ), only one patient developed grade 2 neurotoxicity and no patient developed grade 3 or 4.
These observations indicate that further treatment with single-agent docetaxel can be administered once the cumulative dose of doxorubicin necessitates discontinuation of further treatment with the combination. This continuation of treatment with single agent docetaxel was the case for 21 patients in this study (50%) who received a median of three further cycles (one to six) with single-agent docetaxel. Doxorubicin is known to be cardiotoxic and above a cumulative dose of 450-550 mg/m 2 there is a significant increase in the risk of irreversible congestive heart failure (CHF) [11, 12, 18] .
In our study, no patient developed CHF despite being exposed to a relatively high cumulative dose of doxorubicin (median cumulative dose: 392 mg/m 2 , range: 240-559 mg/m 2 ) and then observed for a long time period (median follow-up 29 months). In addition, very few patients developed LVEF decrease according to Schwartz's criteria [19] and all but one had a complete recovery. Similar results have been reported in another trial in which docetaxel 75 mg/m 2 and doxorubicin 50 mg/m 2 are being administered with cyclophosphamide 500 mg/m 2 to a similar, but anthracycline-nai've, patient population [20] . To date, with a median follow-up of 15 months (5+-21) and a median cumulative dose of doxorubicin of 392 mg/m 2 (49-419), only one case of CHF has been observed among 54 treated patients [20] .
In addition, we have recently completed at Institut Curie and Hopital Paul Brousse a phase II trial in which 45 first-line metastatic breast cancer patients were treated with this combination at the dose of docetaxel 75 mg/m 2 and doxorubicin 50 mg/m 2 . With a median follow up of more than one year, no CHF has been noted to date.
A 20% incidence of CHF was observed in two studies when doxorubicin was combined to paclitaxel given over three hours and a short interval between the two drugs (cumulative dose of doxorubicin 420 and 369 mg/m 2 ). It appears that a lower cumulative dose of anthracycline, increased paclitaxel infusion duration, and/or increased interval between the two drugs, seem to be effective strategies for avoiding the increase in CHF caused by combining paclitaxel with doxorubcin, but this may affect activity [14, [21] [22] [23] [24] [25] .
The pharmacokinetic interaction described between paclitaxel given over three hours infusion and doxorubicin may be the reason for the enhancement of doxorubicin cardiotoxicity [26] . In Gianni's pharmacokinetic study, paclitaxel was responsible for a non-linear disposition of doxorubicin and doxorubicinol. The result was persistently elevated plasma concentrations of doxorubicin and doxorubicinol which might, in part, explain the high antitumor activity and the high incidence of cardiac toxicity observed in this study. This also suggests that even minor modifications to the dose and infusion duration of either drug may result in unpredictable pharmacodynamic consequences.
In contrast, docetaxel does not change the pharmacokinetic profile of doxorubicin, as recently demonstrated in two separate trials. In the first, a pharmacokinetic study was performed in 12 patients receiving doxorubicin 50 mg/m 2 followed by docetaxel 75 mg/m 2 , either after a one-hour interval (in the first six patients) or immediately followed by docetaxel (n = 6). The study aim was to explore any potential interaction between doxorubicin, doxorubicinol and docetaxel. The results indicate that docetaxel does not change the pharmacokinetic profile of doxorubicin or doxorubicinol and could be administered immediately after doxorubicin i.v. bolus [27] . In the second study, Schuller et al. performed a pharmacokinetic study in 24 patients who received doxorubicin 50 mg/m 2 administered alone (cycle 1), docetaxel 75 mg/m 2 administered alone (cycle 2), or both drugs at the same doses (cycle 3) in the same patient. Twelve patients received the two drugs with a one hour interval, and 12 without, and the results indicated that docetaxel did not alter doxorubicin area under the curve [28] .
Although efficacy assessment was not the primary end point in our trial, the homogeneous patient population allows us to draw some conclusions on the efficacy of this combination. A high level of activity was observed at all dose levels, in particular at the last four doses levels containing docetaxel at doses ^ 60 mg/m 2 and doxorubicin > 50 mg/m 2 . The overall response rate was 81% (95% CI: 62.5-92.5). However, the complete response rate was low (5%). This could be related to the high prevalence of patients with bone metastases, visceral involvement, relatively high tumor burden, and prior adjuvant chemotherapy. Despite the high prevalence of these unfavorable patient characteristics, responses were observed at all disease sites, including a high response rate in patients with liver or visceral involvement. Although prior adjuvant chemotherapy has been shown to adversely affect response rate in patients with metastatic breast cancer [29, 30] , the activity in this trial was high in 22 patients who had received prior adjuvant anthracyclines.
With 29 months follow-up, the range of duration of response was 6+-62 weeks, but most responders did not progress before censoring for further therapy. The median time to progression was 46 weeks (6+-62), and median survival had not yet been reached. The median duration of response without censoring for hormonotherapy was 71 weeks (15-137+), based on 14 progressive events (5 before further therapy, 9 after HT) in the 30 responders. The median time to progression without censoring for hormonotherapy was 62 weeks (12-142+) . By March 1998, 64% of patients were still alive and 15 had died.
In summary, docetaxel in combination with doxorubicin is a feasible and active combination and was not associated with CHF in the 42 patients in this study. Results of ongoing phase III trials comparing docetaxel/doxorubicin AT to AC and TAC to FAC as firstline chemotherapy in patients with metastatic breast cancer will definitively answer the question of the role of docetaxel in combination with doxorubicin in this setting. The combination is currently also being tested in early breast cancer patients.
